Literature DB >> 26169267

Induction of Multifunctional Broadly Reactive T Cell Responses by a Plasmodium vivax Circumsporozoite Protein Recombinant Chimera.

Monica Cabrera-Mora1, Jairo Andres Fonseca1, Balwan Singh1, Joseli Oliveira-Ferreira2, Josué da Costa Lima-Junior2, J Mauricio Calvo-Calle3, Alberto Moreno4.   

Abstract

Plasmodium vivax is the most widespread species of Plasmodium, causing up to 50% of the malaria cases occurring outside sub-Saharan Africa. An effective vaccine is essential for successful control and potential eradication. A well-characterized vaccine candidate is the circumsporozoite protein (CSP). Preclinical and clinical trials have shown that both antibodies and cellular immune responses have been correlated with protection induced by immunization with CSP. On the basis of our reported approach of developing chimeric Plasmodium yoelii proteins to enhance protective efficacy, we designed PvRMC-CSP, a recombinant chimeric protein based on the P. vivax CSP (PvCSP). In this engineered protein, regions of the PvCSP predicted to contain human T cell epitopes were genetically fused to an immunodominant B cell epitope derived from the N-terminal region I and to repeat sequences representing the two types of PvCSP repeats. The chimeric protein was expressed in soluble form with high yield. As the immune response to PvCSP has been reported to be genetically restricted in the murine model, we tested the immunogenicity of PvRMC-CSP in groups of six inbred strains of mice. PvRMC-CSP was able to induce robust antibody responses in all the mouse strains tested. Synthetic peptides representing the allelic forms of the P. vivax CSP were also recognized to a similar extent regardless of the mouse strain. Furthermore, the immunization regimen induced high frequencies of multifunctional CD4(+) and CD8(+) PvRMC-CSP-specific T cells. The depth and breadth of the immune responses elicited suggest that immunization with PvRMC-CSP can circumvent the genetic restriction of the immune response to P. vivax CSP. Interestingly, PvRMC-CSP was also recognized by naturally acquired antibodies from individuals living in areas where malaria is endemic. These features make PvRMC-CSP a promising vaccine candidate for further development.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26169267      PMCID: PMC4534670          DOI: 10.1128/IAI.00480-15

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  72 in total

1.  Alternate interactions define the binding of peptides to the MHC molecule IA(b).

Authors:  Xinqi Liu; Shaodong Dai; Frances Crawford; Rachel Fruge; Philippa Marrack; John Kappler
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-25       Impact factor: 11.205

2.  Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice.

Authors:  Joanne M Lumsden; Saule Nurmukhambetova; Jennifer H Klein; Jetsumon Sattabongkot; Jason W Bennett; Sylvie Bertholet; Christopher B Fox; Steven G Reed; Christian F Ockenhouse; Randall F Howard; Mark E Polhemus; Anjali Yadava
Journal:  Vaccine       Date:  2012-03-13       Impact factor: 3.641

3.  Inhibitory activity of interferons and interleukin 1 on the development of Plasmodium falciparum in human hepatocyte cultures.

Authors:  S Mellouk; R K Maheshwari; A Rhodes-Feuillette; R L Beaudoin; N Berbiguier; H Matile; F Miltgen; I Landau; S Pied; J P Chigot
Journal:  J Immunol       Date:  1987-12-15       Impact factor: 5.422

Review 4.  Plasmodium vivax malaria vaccine development.

Authors:  M Arévalo-Herrera; S Herrera
Journal:  Mol Immunol       Date:  2001-12       Impact factor: 4.407

5.  Circumsporozoite protein heterogeneity in the human malaria parasite Plasmodium vivax.

Authors:  R Rosenberg; R A Wirtz; D E Lanar; J Sattabongkot; T Hall; A P Waters; C Prasittisuk
Journal:  Science       Date:  1989-09-01       Impact factor: 47.728

6.  Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsion.

Authors:  Joanne M Lumsden; Sathit Pichyangkul; Utaiwan Srichairatanakul; Kosol Yongvanitchit; Amporn Limsalakpetch; Saule Nurmukhambetova; Jennifer Klein; Sylvie Bertholet; Thomas S Vedvick; Steven G Reed; Jetsumon Sattabongkot; Jason W Bennett; Mark E Polhemus; Christian F Ockenhouse; Randall F Howard; Anjali Yadava
Journal:  Infect Immun       Date:  2011-06-20       Impact factor: 3.441

7.  Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses.

Authors:  Arturo Reyes-Sandoval; Tamara Berthoud; Nicola Alder; Loredana Siani; Sarah C Gilbert; Alfredo Nicosia; Stefano Colloca; Riccardo Cortese; Adrian V S Hill
Journal:  Infect Immun       Date:  2009-10-26       Impact factor: 3.441

8.  A long neglected world malaria map: Plasmodium vivax endemicity in 2010.

Authors:  Peter W Gething; Iqbal R F Elyazar; Catherine L Moyes; David L Smith; Katherine E Battle; Carlos A Guerra; Anand P Patil; Andrew J Tatem; Rosalind E Howes; Monica F Myers; Dylan B George; Peter Horby; Heiman F L Wertheim; Ric N Price; Ivo Müeller; J Kevin Baird; Simon I Hay
Journal:  PLoS Negl Trop Dis       Date:  2012-09-06

9.  A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach.

Authors:  Peng Wang; John Sidney; Courtney Dow; Bianca Mothé; Alessandro Sette; Bjoern Peters
Journal:  PLoS Comput Biol       Date:  2008-04-04       Impact factor: 4.475

10.  NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11.

Authors:  Claus Lundegaard; Kasper Lamberth; Mikkel Harndahl; Søren Buus; Ole Lund; Morten Nielsen
Journal:  Nucleic Acids Res       Date:  2008-05-07       Impact factor: 16.971

View more
  8 in total

1.  Inclusion of the murine IgGκ signal peptide increases the cellular immunogenicity of a simian adenoviral vectored Plasmodium vivax multistage vaccine.

Authors:  Jairo A Fonseca; Jessica N McCaffery; Juan Caceres; Elena Kashentseva; Balwan Singh; Igor P Dmitriev; David T Curiel; Alberto Moreno
Journal:  Vaccine       Date:  2018-04-12       Impact factor: 3.641

2.  Evaluation of the malaria elimination policy in Brazil: a systematic review and epidemiological analysis study.

Authors:  J O Melo; M A O Padilha; R T A Barbosa; W J Alonso; A Y Vittor; G Z Laporta
Journal:  Trop Biomed       Date:  2020-06       Impact factor: 0.717

3.  A chimeric protein-based malaria vaccine candidate induces robust T cell responses against Plasmodium vivax MSP119.

Authors:  Jairo Andres Fonseca; Monica Cabrera-Mora; Balwan Singh; Joseli Oliveira-Ferreira; Josué da Costa Lima-Junior; J Mauricio Calvo-Calle; Jose Manuel Lozano; Alberto Moreno
Journal:  Sci Rep       Date:  2016-10-06       Impact factor: 4.379

4.  Rational development of a protective P. vivax vaccine evaluated with transgenic rodent parasite challenge models.

Authors:  Ahmed M Salman; Eduardo Montoya-Díaz; Heather West; Amar Lall; Erwan Atcheson; Cesar Lopez-Camacho; Jai Ramesar; Karolis Bauza; Katharine A Collins; Florian Brod; Fernando Reis; Leontios Pappas; Lilia González-Cerón; Chris J Janse; Adrian V S Hill; Shahid M Khan; Arturo Reyes-Sandoval
Journal:  Sci Rep       Date:  2017-04-18       Impact factor: 4.379

5.  Rationale for Further Development of a Vaccine Based on the Circumsporozoite Protein of Plasmodium vivax.

Authors:  Anjali Yadava; Norman C Waters
Journal:  PLoS Negl Trop Dis       Date:  2017-01-12

6.  Chloroquine and mefloquine resistance profiles are not related to the circumsporozoite protein (CSP) VK210 subtypes in field isolates of Plasmodium vivax from Manaus, Brazilian Amazon.

Authors:  Lilian Rose Pratt-Riccio; Bárbara de Oliveira Baptista; Vanessa Rodrigues Torres; Cesare Bianco-Junior; Daiana de Souza Perce-Da-Silva; Evelyn Kety Pratt Riccio; Josué da Costa Lima-Junior; Paulo Renato Rivas Totino; Gustavo Capatti Cassiano; Luciane Moreno Storti-Melo; Ricardo Luiz Dantas Machado; Joseli de Oliveira-Ferreira; Dalma Maria Banic; Leonardo José de Moura Carvalho; Cláudio Tadeu Daniel-Ribeiro
Journal:  Mem Inst Oswaldo Cruz       Date:  2019-08-12       Impact factor: 2.743

7.  Structural basis of Plasmodium vivax inhibition by antibodies binding to the circumsporozoite protein repeats.

Authors:  Iga Kucharska; Lamia Hossain; Danton Ivanochko; Qiren Yang; John L Rubinstein; Régis Pomès; Jean-Philippe Julien
Journal:  Elife       Date:  2022-01-13       Impact factor: 8.140

8.  A Plasmodium Promiscuous T Cell Epitope Delivered within the Ad5 Hexon Protein Enhances the Protective Efficacy of a Protein Based Malaria Vaccine.

Authors:  Jairo Andres Fonseca; Monica Cabrera-Mora; Elena A Kashentseva; John Paul Villegas; Alejandra Fernandez; Amelia Van Pelt; Igor P Dmitriev; David T Curiel; Alberto Moreno
Journal:  PLoS One       Date:  2016-04-29       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.